News
ADTX
0.0012
-57.14%
-0.0016
Aditxt Subsidiary Ends SPAC Deal, Explores Alternatives
TipRanks · 1d ago
Weekly Report: what happened at ADTX last week (1005-1009)?
Weekly Report · 5d ago
Weekly Report: what happened at ADTX last week (0928-1002)?
Weekly Report · 10/05 09:58
Weekly Report: what happened at ADTX last week (0921-0925)?
Weekly Report · 09/28 09:55
Aditxt Faces Nasdaq Delisting, Moves Fully to OTC
TipRanks · 09/23 16:34
Weekly Report: what happened at ADTX last week (0914-0918)?
Weekly Report · 09/21 09:55
Nasdaq says to delist Nuvve Holding, Maxeon Solar, Sangamo
TipRanks · 09/17 13:35
Weekly Report: what happened at ADTX last week (0907-0911)?
Weekly Report · 09/14 09:59
Weekly Report: what happened at ADTX last week (0831-0904)?
Weekly Report · 09/07 09:54
Weekly Report: what happened at ADTX last week (0824-0828)?
Weekly Report · 08/31 09:59
Weekly Report: what happened at ADTX last week (0817-0821)?
Weekly Report · 08/24 10:00
Aditxt Divests Pearsanta Stake, Retains Royalty Upside
TipRanks · 08/19 21:04
Weekly Report: what happened at ADTX last week (0810-0814)?
Weekly Report · 08/17 10:01
Weekly Report: what happened at ADTX last week (0803-0807)?
Weekly Report · 08/10 09:57
Weekly Report: what happened at ADTX last week (0727-0731)?
Weekly Report · 08/03 09:56
Weekly Report: what happened at ADTX last week (0720-0724)?
Weekly Report · 07/27 10:00
Weekly Report: what happened at ADTX last week (0713-0717)?
Weekly Report · 07/20 09:57
Aditxt amends note agreement, expands secured financing
TipRanks · 07/17 17:28
Weekly Report: what happened at ADTX last week (0706-0710)?
Weekly Report · 07/13 09:58
Weekly Report: what happened at ADTX last week (0629-0703)?
Weekly Report · 07/06 10:01
More
Webull provides a variety of real-time ADTX stock news. You can receive the latest news about Aditxt Inc through multiple platforms. This information may help you make smarter investment decisions.
About ADTX
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. The Company operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimune’s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. It is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.